Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

about

The Servier oncology pipeline in 2017.Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.

P2860

Q38692664-E3154DF7-6586-4C7E-89BC-54A8FAADFBAB Q55504476-F89B15CB-95AD-41AD-91A4-F1A77FAC62AA

P2860

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

Item

http://www.wikidata.org/entity/Q38984987

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

@en

type

Item

label

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

@en

prefLabel

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

@en

P1476

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

@en

P2860

Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent

Cancer treatment-related cardiac toxicity: prevention, assessment and management.

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for h

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.

P2888

s40265-016-0650-8

P304

1579-1586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0650-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2016-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040146618

http://www.w3.org/2001/XMLSchema#string

P698

27757832

http://www.w3.org/2001/XMLSchema#string

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

about

P2860

P2860

Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698